SCHEMBL12385752

SCHEMBL12385752

CCC1(O)CCC(C(C)C)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26685186 1.00
SCHEMBL19364854 1.00
SCHEMBL12384744 0.82 ESR2 (0.41)
SCHEMBL12385880 0.82 ESR2 (0.41)
SCHEMBL17897996 0.82 ESR2 (0.41)
SCHEMBL12444577 0.80
SCHEMBL12444578 0.80
SCHEMBL16786406 0.76
SCHEMBL1569022 0.74
SCHEMBL25156997 0.74 EPHX1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339937-A1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS SATO PHARMACEUTICAL CO., LTD. (JP) 2023-10-26 US disclosed
US-10988482-B2 IRAK4 inhibitor and use thereof Beijing Hanmi Pharmaceutical Co., Ltd. (CN) 2021-04-27 US disclosed
EP-3336091-B1 IRAK4 INHIBITOR AND USE THEREOF BEIJING HANMI PHARMACEUTICAL CO LTD (CN) 2020-12-02 EP disclosed
US-20200062775-A1 IRAK4 INHIBITOR AND USE THEREOF Beijing Hanmi Pharmaceutical Co., Ltd. (CN) 2020-02-27 US disclosed
EP-3336091-A1 IRAK4 INHIBITOR AND USE THEREOF Beijing Hanmi Pharmaceutical Co., Ltd. (CN) 2018-06-20 EP disclosed
US-20110201593-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2011-08-18 US disclosed